Physician profile
John Diana
NPI 1649297540
$981,059.08
in general payments reported to CMS, 2019-2025
9 companies · $138K in 2025
The $138K reported for 2025 was more than what 94% of Adult Reconstructive Orthopaedic Surgery providers received nationally (typical 2025 total: $1,425).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143K · 2020: $141K · 2021: $120K · 2022: $127K · 2023: $154K · 2024: $158K · 2025: $138K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $446K · Food and Beverage: $2,864 · Travel and Lodging: $1,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $446,100.36 |
| Food and Beverage | $2,863.57 |
| Travel and Lodging | $1,427.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Development Corporation | $966,754.92 | 2019-2025 | |
| Stryker Corporation | $10,870.51 | 2019-2024 | Mako |
| Zimmer Biomet Holdings, INC. | $2,536.46 | 2019-2025 | Rosa, Taperloc, Persona |
| Avanos Medical | $478.21 | 2019-2025 | On-Q* Pump and Accessories, On-Q Pump and Accessories |
| Heron Therapeutics, INC. | $115.34 | 2025 | Zynrelef, Aponvie |
| Medacta USA, INC. | $115.16 | 2025 | Quadra |
| Depuy Synthes Sales INC. | $86.60 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $51.79 | 2025 | |
| Osteoremedies, LLC | $50.09 | 2025 | Remedy Spacer, Remedy Spectrum Gv Spacer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Diana listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.